DPU receives research funding for personalized medicine and diagnostics

DANUBE Private University (DPU) starts three new research projects that deal with cutting -edge medical questions. The projects will be funded with over 1.2 million euros by the EU Structural Fund IBW/EFRE and the economic and tourism fund of the state of Lower Austria. The projects make a significant contribution to the further development of personalized medicine, infection diagnostics and microbiom research.

“These funding commitments are a strong sign of the scientific quality and social relevance of our research. They show that we not only convey knowledge at the DPU, but are also actively working on solutions for tomorrow’s health issues.” Robert Wagner, director of Danube Private University

High -sensitive diagnosis of the microbiome

DANUBE Private University (DPU) starts on August 1, 2025, the future -oriented research project “Mikromoni” under the direction of Dr. Ann-Kathrin Kissmann (University of Ulm), who could be won by the DPU for this project. It is devoted to the development of an innovative platform for fast, precise and quantitative analysis of living bacteria in the human microbiome. Univ.-Prof. Dr. Christoph Kleber, head of the research & development at DANUBE private university.

At the center of the project with a term of two years is also the development of a new diagnostic technology based on graphs-based field effect transistors (GFETS) and nucleic acid-based aptamers, which are obtained by an in-vitro evolution process (SELEX). This combination enables the direct detection of living bacteria – for example from stool samples – with a detection limit of only 10 cells/ml.

Compared to conventional methods, a significantly faster and more specific analysis is to be achieved. The aim is to develop a multiplexable platform, which can also quantify up to eight different microorganisms from complex samples such as stool, water or soil.

The project makes a significant contribution to medical research by opening new ways to the early diagnosis of microbiomassodized diseases. Disorders in the balance of microbioma-so-called dysbioses-are related to a variety of diseases, including chronic inflammatory bowel diseases, cancer, metabolic disorders and neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

Artificial intelligence for personalized cancer therapy

On September 1, 2025, the starting signal for the research project “Ai Predictchemo” under the direction of Ass.-Prof. Dr. Sepideh Hatamikia. The aim of the project with a runtime of two years is to develop AI-based software, which can predict how well breast cancer patients will address on a neoadjuvant chemotherapy (NACT).

The basis for this is preoperative MRI data that should make it possible to make individual therapy decisions-with the aim of avoiding unnecessary side effects and making treatment more targeted. The system is trained and validated with anonymized patients of the “State Clinic Wiener Neustadt”. The close cooperation with the Wiener Neustadt hospital and the Lower Austrian State Health Agency ensures access to high -quality clinical data and strengthens the medical relevance of the project.

“Ai Predictchemo” addresses a central challenge in oncology: The lack of the possibility of reliably assessing the success of chemotherapy in advance. By combining medical expertise and modern AI technology, the project makes an important contribution to personalizing medicine, evidence-based decision-making and for the safe integration of AI into clinical practice.

Recognize tuberculosis early and simply – with breathing air

Every year around 10.6 million people develop tuberculosis (TB) worldwide, about 1.6 million die of it. Particularly alarming: According to the WHO, up to 40 % of cases are not diagnosed or reported – this number is even 70 % in children. An easily accessible diagnostic tool, such as a test strip, could reduce the disease and death rate by up to 50 %.

The TB-Breath project under the direction of Prof. Dr. Mandana Amiri started on May 1, 2025 – with a term of 24 months. The goal is to use the immense potential of biomarkers in the breath condensate for real-time analysis of tuberculosis. The development of new TB bioreceptors and their connection to electrochemical biosensors is the central part of the project to easily enable TB diagnostics at any time.

TB-Breath makes a significant contribution to medical research by combining biomedical sensors, nanotechnology and clinical application. The development of new bioreceptors and their integration into electrochemical biosensors opens up new ways for early, mobile and inexpensive tuberculosis diagnostics, especially in underserved regions.

keluaran hk

keluaran sdy

keluaran sdy

togel

By adminn